TITLE

THE HATCH-WAXMAN ACT AND MARKET EXCLUSIVITY FOR GENERIC DRUG MANUFACTURERS: AN ENTITLEMENT OR AN INCENTIVE?

AUTHOR(S)
Mehl, Ashlee B.
PUB. DATE
June 2006
SOURCE
Chicago-Kent Law Review;2006, Vol. 81 Issue 2, p649
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
One of Congress' central goals in enacting the Hatch-Waxman Act was to expedite and encourage earlier market entry for generic pharmaceutical products. The Act provides that a generic firm may challenge a drug patent during its term by filing paperwork with the FDA that alleges either that its generic product does not infringe the relevant patent, or that the patent is invalid. If the patentee disagrees with the allegation of the generic firm, it may file suit and have a court determine infringement and validity. If the generic firm prevails in court on either count, it may enter the market with its generic drug immediately, despite the patent protection that would have otherwise prevented its market entry. In order to encourage generic firms to pursue such challenges to pioneer patents earlier during the patent terms, Congress included a generic exclusivity provision in the Act, which rewards the first generic firm to challenge a pioneer patent with 180 days of generic market exclusivity, during which time no other generic version of that drug may enter the market. As the provision is currently interpreted, market exclusivity is provided to the generic firm that is first-in-time to file a challenge against the patent, regardless of whether that firm subsequently prevails in establishing patent invalidity or non-infringement. This Note examines the dispute that arose out of the generic exclusivity provision, critiques the current state of generic exclusivity law in light of recent congressional amendments, and proposes that Congress further amend the Act to require forfeiture of generic exclusivity when the first generic firm to file a challenge against the pioneer patent is not also the first to complete a successful challenge to that pioneer patent.
ACCESSION #
22756121

 

Related Articles

  • Top Generic-Drug Firms Go Into Branded. DAVID SAITO-CHUNG // Investors Business Daily;10/7/2014, pB06 

    In the past, it was easy to separate the ethical-drug makers that marketed proprietary medicines and the generics makers that specialized in making copies of such branded medicines.

  • Generics enter 'Golden Age,' but hurdles remain. Baltazar, Amanda // Drug Store News;8/13/2007, Vol. 29 Issue 10, p87 

    The article focuses on the challenges faced by generic drug manufacturers despite the growing opportunities presented to them by patent expirations of drugs manufactured by big firms in the U.S. One outcome of the opportunities for generic drug makers is a diminishing number of firms in the U.S....

  • Generic Drugs Face Regulatory and Scientific Challenges. Wechsler, Jill // BioPharm International;Aug2013, Vol. 26 Issue 8, p10 

    The article discusses legislative, regulatory and scientific challenges facing the generic drugs sector. The developments in the sector as the U.S. Food and Drug Administration (FDA) celebrates the one-year anniversary of the Generic Drug User Fee Amendments (GDUFA) of 2012 are discussed. The...

  • Drugstores Face the Wal-Mart Factor. Gaudio, Thomas // njbiz;10/30/2006, Vol. 19 Issue 44, p1 

    The article talks about the national campaign of Wal-Mart to discount generic drugs. Wal-Mart charged $4 for a month's supply of different generic drugs in 27 states. Local independent pharmacists are not worried for the competition against Wal-Mart and their low price. Pharmacists assert that...

  • Comment on "The economics of follow-on drug research and development: trends in entry rates and the timing of development". Hollis, Aidan // PharmacoEconomics;2005, Vol. 23 Issue 12, p1187 

    The article presents and explores some useful empirical facts about 'me-too' drugs. These drugs, which are sometimes called follow-on drugs, are products that largely duplicate the action of existing drugs. Pharmaceutical industry players are becoming concern regarding the increasing extent to...

  • Best may be yet to come for generic drug makers. Kirsche, Michelle L. // Drug Store News;2/14/2005, Vol. 27 Issue 2, p28 

    Reports on the research-and-development pipeline of drug makers in the U.S. Sales of generic companies; Factors contributing to the performance of drug makers; Development of generic pipeline.

  • GPhA bullish on generic industry's future. Cohen, Harold E. // Drug Topics;5/7/2001, Vol. 145 Issue 9, p64 

    Provides information on the Generic Pharmaceutical Association (GPhA), a unification of the generic industry in the United States. Significance of the formation of a united front for the generic industry; Goals of the association; Strategy of pharmacy benefit managers.

  • Is the Generics Industry Ready for Multi-Source Biologics? Challener, Cynthia // Chemical Market Reporter;04/23/2001, Vol. 259 Issue 17, p14 

    Deals with the generic biologic industry. Estimated growth of the biopharmaceutical generics market; Details on the acquisition of Indiana Protein Technologies by Ivax Corp.; European firms preparing to participate in the marketing and sales of generic biopharmaceuticals; Risks faced by a...

  • Report from: Japan. Wan, Jane // Pharmaceutical Technology;May2009, Vol. 33 Issue 5, p18 

    The article focuses on the efforts of the Japanese government in implementing generic drugs and its impact to the healthcare system in Japan. It mentions that generic drug substitution was introduced to the public in April 2006 and cites the cooperation of doctors in rendering prescriptions and...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics